Tomé, Sandra O.
Vandenberghe, Rik
Ospitalieri, Simona
Van Schoor, Evelien
Tousseyn, Thomas
Otto, Markus
von Arnim, Christine A. F.
Thal, Dietmar Rudolf
Funding for this research was provided by:
Alzheimer Forschung Initiative (#13803)
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043)
Mady Browaeys Fund for Research into Frontotemporal Lobar Degeneration
Bundesministerium für Bildung und Forschung (FTLDc)
Article History
Received: 13 April 2020
Accepted: 15 April 2020
First Online: 29 April 2020
Ethics approval and consent to participate
: All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases was granted by the ethical committee of Ulm University (Germany) and UZ/KU-Leuven ethical committee (Belgium). This study covering the retrospective analysis of samples and data was approved by the UZ/KU-Leuven ethical committee (S-59295) (Belgium).
: Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
: DRT received speaker honorary from Novartis Pharma AG (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Hong Kong University Research council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2019) and Dr. Willmar Schwabe GmbH &Co. KG (2014–2019).MO served as consultant for Axon neuroscience and Fujirebio and gave invited talks for Roche and Fujirebio.